Literature DB >> 25093538

Total synthesis and conformational analysis of apratoxin C.

Yuichi Masuda1, Jun Suzuki, Yuichi Onda, Yuta Fujino, Masahito Yoshida, Takayuki Doi.   

Abstract

Total synthesis of apratoxin C, a cyanobacterial cyclodepsipeptide with highly potent cytotoxicity against some cancer cell lines, was achieved using the apratoxin A synthetic strategy developed by us. To elucidate the relationship between conformation and activity, the tertiary structure of apratoxin C was analyzed by NMR spectroscopy. We obtained 37 ROEs and five (3)JH,H values, which were translated into distance and dihedral angle constraints, respectively. Molecular modeling was performed with a restrained conformational search by a distance geometry method. The lowest energy structure indicated that the methyl group at C37 and the isopropyl group at C39 play critical roles in maintaining the conformation, whereas the methyl group at C34 does not. Moreover, we confirmed that apratoxin A and C possess similar conformations, providing a likely explanation for their nearly equivalent cytotoxicities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25093538     DOI: 10.1021/jo501130b

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  3 in total

1.  Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.

Authors:  Weijing Cai; Qi-Yin Chen; Long H Dang; Hendrik Luesch
Journal:  ACS Med Chem Lett       Date:  2017-09-18       Impact factor: 4.345

Review 2.  Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.

Authors:  Su Xu; Bhavitavya Nijampatnam; Shilpa Dutta; Sadanandan E Velu
Journal:  Mar Drugs       Date:  2016-01-12       Impact factor: 5.118

3.  Asymmetric Synthesis of the C15⁻C32 Fragment of Alotamide and Determination of the Relative Stereochemistry.

Authors:  Hao-Yun Shi; Yang Xie; Pei Hu; Zi-Qiong Guo; Yi-Hong Lu; Yu Gao; Cheng-Gang Huang
Journal:  Mar Drugs       Date:  2018-10-30       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.